NCT Number: NCT06312670
Phase: PHASE2
Trial Summary: The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer. The main goals of this study are to evaluate the antitumo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Pedro Barata, MD, MSc
Acronym:
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives